Immunotherapy News and Research

Latest Immunotherapy News and Research

Researchers create first ever atlas of immune cells in the human body

By analyzing tissues harvested from organ donors, Columbia University Medical Center (CUMC) researchers have created the first ever "atlas" of immune cells in the human body.

21 Dec 2012

EMD Serono's L-BLP25 Phase III NSCLC trial does not meet primary endpoint

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).

19 Dec 2012

New technique could help develop more-specific, cell-based immune therapies for cancer

A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development of more-specific, cell-based immune therapies for cancer.

17 Dec 2012

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2012.

14 Dec 2012

CRI, SU2C form Cancer Immunology Translational Research Dream Team

Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology - "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy."

13 Dec 2012

Delayed childbearing may protect against triple-negative breast cancer

Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study.

12 Dec 2012

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them. Blocking myeloid-derived suppressor cells and regulatory T-cell reconstitution improved adoptive T-cell therapy, an immunotherapy designed to suppress tumor activity.

12 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.

9 Dec 2012

Scancell announces preliminary results from Part 1 of ImmunoBody vaccine Phase 1/2 MM trial

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce preliminary results from Part 1 of the Phase 1/2 clinical trial of its DNA ImmunoBody vaccine in patients with Stage III/IV malignant melanoma.

6 Dec 2012

Rethinking therapy decisions in autoimmune encephalopathy

Researchers say that diagnosis and management of encephalopathies may need to be rethought, as many patients who test negative for the relevant antibody still benefit from immunotherapy.

4 Dec 2012

Data from OncoSec Medical clinical studies to be presented at DNA Vaccines 2012 Conference

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference.

4 Dec 2012

Certain patients with prostate cancer may benefit from Provenge clinical trial

Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.

4 Dec 2012

New study finds chemicals used for water purification can lead to food allergies

Food allergies are on the rise, affecting 15 million Americans. And according to a new study published in the December issue of Annals of Allergy, Asthma and Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), pesticides and tap water could be partially to blame.

3 Dec 2012

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, has just announced successful completion of the first clinical development phase for VAC-3S immunotherapy in the treatment of HIV infections.

30 Nov 2012

CEL-SCI's Multikine cancer drug receives key Japanese patent

CEL-SCI Corporation today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection).

29 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

Alzheimer's therapeutic trials have gotten bad press lately, but it is not all gloom and doom. As evident at the 5th Clinical Trials in Alzheimer's Disease (CTAD) conference, held 29-31 October in the Principality of Monaco, scientists keep extracting new data from recent drug trials to gear up for a round of new ones that aim to tackle Alzheimer's earlier than ever before.

21 Nov 2012

Immunotherapy News and Research

Latest Immunotherapy News and Research

Researchers create first ever atlas of immune cells in the human body

EMD Serono's L-BLP25 Phase III NSCLC trial does not meet primary endpoint

New technique could help develop more-specific, cell-based immune therapies for cancer

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

CRI, SU2C form Cancer Immunology Translational Research Dream Team

Delayed childbearing may protect against triple-negative breast cancer

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

New hope for leukemia patients

Ibrutinib may effectively combat chronic lymphocytic leukemia

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Scancell announces preliminary results from Part 1 of ImmunoBody vaccine Phase 1/2 MM trial

Rethinking therapy decisions in autoimmune encephalopathy

Data from OncoSec Medical clinical studies to be presented at DNA Vaccines 2012 Conference

Certain patients with prostate cancer may benefit from Provenge clinical trial

New study finds chemicals used for water purification can lead to food allergies

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

CEL-SCI's Multikine cancer drug receives key Japanese patent

mRNA vaccines offer protection against influenza A virus infections in various animal models

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in